ImmunoGen prices common stock public offering at $8.00 per share

NewsGuard 100/100 Score
May 7 2010

ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, announced today that it has priced a public offering of 9,000,000 shares of its common stock at a price of $8.00 per share. Net proceeds, after underwriting discounts and commissions and expenses, will be approximately $67.4 million. ImmunoGen has granted the underwriters a thirty (30) day option to purchase up to 1,350,000 additional shares to cover over-allotments, if any. The offering is expected to close on or about May 12, 2010, subject to satisfaction of customary closing conditions.

J.P. Morgan Securities Inc. is acting as the sole book-runner for the offering and Oppenheimer & Co. Inc., RBC Capital Markets Corporation, Cantor Fitzgerald & Co. and Morgan Joseph & Co. Inc. are acting as co-managers.

SOURCE ImmunoGen, Inc.

Posted in:

Tags: , , , , , ,

Comments (0)

Suggested Reading

Study suggests high levels of vitamin B3 breakdown products are linked to higher risk of mortality, heart attacks, and stroke
Study reveals inflammation's role in long COVID's lingering effects
Mapping the Microbiome: Dr. Abidemi Junaid on the Groundbreaking Vagina Chip
Vaccines targeting chronic diseases show promise in combatting age-related conditions
CN Bio PhysioMimix Organ-on-a-Chip data supports Inipharm’s INI-822 for metabolic liver disease treatment now in clinical testing
Natural compounds show promise in modulating heme breakdown, offering new therapeutic avenues
New peptide library paves the way for targeting elusive cancer factor MYC
Tackling Antimicrobial Resistance Together: A Conversation with Dr. Beverley Isherwood

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Natural killer cells lead the charge in cancer treatment innovation